Del-zota News, Researches and Articles

About us

We do not want children to die from a disease that can be cured. We want to give hope to families and ensure that all children with DMD are treated and regain their health.

Latest Articles

Givinostat’s Exclusive Distribution Agreement in 17 Central and Eastern European Countries, Including the Baltic States, has been Announced by Italfarmaco and Medis

Press Releases March 18, 2025 0

Italfarmaco and Medis, a leading pharmaceutical commercialisation company in...

Biophytis’ BIO101 Therapy for Treatment of Sarcopenia Could Bring Hope to Duchenne Muscular Dystrophy Patients

Press Releases March 18, 2025 0

The Phase 2 clinical trial SARA-INT was published in...

Eteplirsen (Exondys 51) Treatment Significantly Slows Heart Function Decline in Duchenne Muscular Dystrophy

Press Releases March 18, 2025 0

Following promising results in slowing heart function decline in...

Frequently Asked Questions About Elevidys Used for Duchenne Muscular Dystrophy

Approved Treatments December 26, 2024 5

A genetic condition known as Duchenne muscular dystrophy (DMD)...

Cures of Duchenne (List of All Researches)

Research September 20, 2024 13

Dystrophin Gene Therapy MechanismCompanyDrugStatus Micro-dystrophin Gene Replacement Sarepta TherapeuticsElevidys/SRP-9001ApprovedMicro-dystrophin Gene ReplacementPfizerPF-06939926DiscontinuedMicro-dystrophin Gene...

Capricor Therapeutics Submits Application for Treatment of DMD Cardiomyopathy

Research October 10, 2024 0

Capricor Therapeutics, a biotechnology company developing transformative cell and...

Del-zota

Must Read

The Challenge of Getting DMD Gene Therapy: Is Geography Destiny?

Satellos Announces Completed Enrollment of Phase 1 Clinical Trial of SAT-3247 in Healthy Volunteers

Sarcomatrix to Present its Latest Advancements in the Development of its Lead Drug Candidate, S-969

About us

Latest Articles

Givinostat’s Exclusive Distribution Agreement in 17 Central and Eastern European Countries, Including the Baltic States, has been Announced by Italfarmaco and Medis

Biophytis’ BIO101 Therapy for Treatment of Sarcopenia Could Bring Hope to Duchenne Muscular Dystrophy Patients

Eteplirsen (Exondys 51) Treatment Significantly Slows Heart Function Decline in Duchenne Muscular Dystrophy

Most Popular

Frequently Asked Questions About Elevidys Used for Duchenne Muscular Dystrophy

Cures of Duchenne (List of All Researches)

Capricor Therapeutics Submits Application for Treatment of DMD Cardiomyopathy